Dose-Finding with Two Agents in Phase I Oncology Trials
From MaRDI portal
Publication:3079137
DOI10.1111/1541-0420.00058zbMath1210.62212OpenAlexW2071941141WikidataQ44644857 ScholiaQ44644857MaRDI QIDQ3079137
Peter F. Thall, Peter Mueller, Sang-Joon Lee, Randall E. Millikan
Publication date: 1 March 2011
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/1541-0420.00058
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50)
Related Items (21)
Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations ⋮ Continual Reassessment Method for Partial Ordering ⋮ Designs for Single- or Multiple-Agent Phase I Trials ⋮ Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering ⋮ Flexible use of copula‐type model for dose‐finding in drug combination clinical trials ⋮ Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information ⋮ Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies ⋮ Determining the Effective Sample Size of a Parametric Prior ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate ⋮ Two‐Dimensional Dose Finding in Discrete Dose Space ⋮ Adaptive designs for selecting drug combinations based on efficacy-toxicity response ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents ⋮ Analysis of ``learn-as-you-go (LAGO) studies ⋮ A Parallel Phase I/II Clinical Trial Design for Combination Therapies
Cites Work
- Unnamed Item
- Optimal Bayesian design applied to logistic regression experiments
- Design and Analysis of Phase I Clinical Trials
- Sampling-Based Approaches to Calculating Marginal Densities
- Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's Window
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Optimum Experimental Designs for Multinomial Logistic Models
This page was built for publication: Dose-Finding with Two Agents in Phase I Oncology Trials
